NCT00504166View on ClinicalTrials.gov

Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women

PHASE4CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

April 30, 2009

Conditions
OsteopeniaOsteoporosis
Interventions
DRUG

alendronate sodium

alendronate sodium 70 mg tablet once week for 24 months

OTHER

placebo comparator

placebo to match alendronate sodium one tablet once a week for 24 months

Trial Locations (1)

94107

University of California Department of Radiology, San Francisco

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT00504166 - Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women | Biotech Hunter | Biotech Hunter